S&P 500   2,997.34 (+1.05%)
DOW   27,047.94 (+0.97%)
QQQ   193.57 (+1.29%)
AAPL   235.90 (+0.01%)
FB   189.05 (+3.15%)
MSFT   141.42 (+1.34%)
CGC   20.05 (+6.31%)
NVDA   196.48 (+5.33%)
MU   46.41 (+3.46%)
TSLA   258.82 (+0.72%)
AMD   30.69 (+0.49%)
T   37.93 (+1.20%)
ACB   3.79 (+7.99%)
NFLX   283.64 (-0.66%)
BAC   29.91 (+2.64%)
S&P 500   2,997.34 (+1.05%)
DOW   27,047.94 (+0.97%)
QQQ   193.57 (+1.29%)
AAPL   235.90 (+0.01%)
FB   189.05 (+3.15%)
MSFT   141.42 (+1.34%)
CGC   20.05 (+6.31%)
NVDA   196.48 (+5.33%)
MU   46.41 (+3.46%)
TSLA   258.82 (+0.72%)
AMD   30.69 (+0.49%)
T   37.93 (+1.20%)
ACB   3.79 (+7.99%)
NFLX   283.64 (-0.66%)
BAC   29.91 (+2.64%)
Log in

Ra Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RARX)

$46.88
-0.06 (-0.13 %)
(As of 10/15/2019 03:24 PM ET)
Today's Range
$46.70
Now: $46.88
$46.96
50-Day Range
$22.90
MA: $27.54
$46.74
52-Week Range
$11.27
Now: $46.88
$46.95
Volume1.35 million shs
Average Volume1.93 million shs
Market Capitalization$2.20 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.34
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RARX
CUSIPN/A
Phone617-401-4060

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.50 million
Book Value$4.92 per share

Profitability

Net Income$-64,940,000.00

Miscellaneous

Employees72
Market Cap$2.20 billion
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive RARX News and Ratings via Email

Sign-up to receive the latest news and ratings for RARX and its competitors with MarketBeat's FREE daily newsletter.


Ra Pharmaceuticals (NASDAQ:RARX) Frequently Asked Questions

What is Ra Pharmaceuticals' stock symbol?

Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX."

How were Ra Pharmaceuticals' earnings last quarter?

Ra Pharmaceuticals Inc (NASDAQ:RARX) announced its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.03. View Ra Pharmaceuticals' Earnings History.

When is Ra Pharmaceuticals' next earnings date?

Ra Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Ra Pharmaceuticals.

What price target have analysts set for RARX?

11 brokers have issued 12 month price objectives for Ra Pharmaceuticals' shares. Their predictions range from $25.00 to $55.00. On average, they expect Ra Pharmaceuticals' share price to reach $46.09 in the next twelve months. This suggests that the stock has a possible downside of 1.8%. View Analyst Price Targets for Ra Pharmaceuticals.

What is the consensus analysts' recommendation for Ra Pharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ra Pharmaceuticals in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ra Pharmaceuticals.

Has Ra Pharmaceuticals been receiving favorable news coverage?

News articles about RARX stock have trended neutral recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ra Pharmaceuticals earned a coverage optimism score of 0.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Ra Pharmaceuticals.

Are investors shorting Ra Pharmaceuticals?

Ra Pharmaceuticals saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 3,300,000 shares, an increase of 24.5% from the August 30th total of 2,650,000 shares. Based on an average trading volume of 464,400 shares, the short-interest ratio is currently 7.1 days. Currently, 8.5% of the shares of the company are short sold. View Ra Pharmaceuticals' Current Options Chain.

Who are some of Ra Pharmaceuticals' key competitors?

What other stocks do shareholders of Ra Pharmaceuticals own?

Who are Ra Pharmaceuticals' key executives?

Ra Pharmaceuticals' management team includes the folowing people:
  • Dr. Douglas A. Treco, Co-Founder, Pres, CEO & Director (Age 61)
  • Mr. David C. Lubner, Exec. VP & CFO (Age 55)
  • Dr. Ramin Farzaneh-Far, Chief Medical Officer (Age 42)
  • Mr. Alonso Ricardo, Chief Technology & Innovation Officer and Head of Research
  • Dr. Simon Read, Chief Scientific Officer (Age 48)

When did Ra Pharmaceuticals IPO?

(RARX) raised $75 million in an initial public offering (IPO) on Wednesday, October 26th 2016. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

How do I buy shares of Ra Pharmaceuticals?

Shares of RARX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ra Pharmaceuticals' stock price today?

One share of RARX stock can currently be purchased for approximately $46.92.

How big of a company is Ra Pharmaceuticals?

Ra Pharmaceuticals has a market capitalization of $2.21 billion and generates $2.50 million in revenue each year. The company earns $-64,940,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Ra Pharmaceuticals employs 72 workers across the globe.View Additional Information About Ra Pharmaceuticals.

What is Ra Pharmaceuticals' official website?

The official website for Ra Pharmaceuticals is http://rapharma.com/.

How can I contact Ra Pharmaceuticals?

Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected]


MarketBeat Community Rating for Ra Pharmaceuticals (NASDAQ RARX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  208 (Vote Outperform)
Underperform Votes:  224 (Vote Underperform)
Total Votes:  432
MarketBeat's community ratings are surveys of what our community members think about Ra Pharmaceuticals and other stocks. Vote "Outperform" if you believe RARX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel